Management of gastrointestinal complaints in differentiated thyroid cancer patients treated with (131)I: comparison of the efficacy of pantoprazole, metoclopramide, and ondansetron - a randomized clinical trial
| Autor: | F. Tabeie, S. Seifollahi, M. Mirzababaee, S. Delavari, Isa Neshandar Asli, L. Fatholahi, Nastaran Baharfar, R. Naghshine, Majid Assadi, M. Motazdian, Babak Shafiei, Hamid Javadi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Metoclopramide Nausea Gastrointestinal Diseases 2-Pyridinylmethylsulfinylbenzimidazoles 030218 nuclear medicine & medical imaging law.invention Ondansetron Iodine Radioisotopes 03 medical and health sciences Hyperemesis gravidarum 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Clinical endpoint Humans Radiology Nuclear Medicine and imaging Thyroid Neoplasms Radiation Injuries Pantoprazole business.industry Proton Pump Inhibitors General Medicine Middle Aged medicine.disease Clinical trial Treatment Outcome 030220 oncology & carcinogenesis Anesthesia Vomiting Antiemetics Female medicine.symptom Radiopharmaceuticals business medicine.drug |
| Zdroj: | Nuklearmedizin. Nuclear medicine. 53(5) |
| ISSN: | 2567-6407 |
| Popis: | SummaryObjective: To compare safety and efficacy of pantoprazol , metoclopramide, ondansetron, as compared to placebo, in controlling gastrointestinal (GI) complaints of thyroid cancer patients treated with I-131these patients. Design: Four-armed, parallel group, single blind, randomized controlled clinical trial, setting: A university hospital, registration: database for clinical trials IRCT2013061713705N1. Patients: 85 patients with differentiated thyroid cancer who received 131I. Main outcome measures: Post- radioiodine nausea and vomiting within three days of therapy (primary endpoint); occurrence of adverse reaction. Results: The patients’ characteristics were similar within the study groups. Among the study variables, age, sex, administered dosage, history of previous GI complaints, and history of hyper- emesis gravidarum in female patients were not statistically different among the groups (p > 0.05). The results revealed that only ondansetron shows a therapeutic benefit over the placebo in controlling nausea (p < 0.05); however, it does not prevent vomiting (p > 0.05). The other two drugs, pantoprazole and metoclopramide, did not control nausea (p > 0.05) or vomiting (p > 0.05). Conclusions: This study may demonstrate that the therapeutic dose of ondansetron could be an effective prophylactic agent in controlling GI complaints in differential thyroid carcinoma (DTC) patients following RAI therapy; however, these preliminary findings should be validated in larger studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|